Business Description
Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm dedicated to creating treatments for a variety of underserviced medical conditions. These include stress-related psychiatric disorders, persistent pain syndromes, and diseases impacting the central nervous system (CNS). The company's approach combines both traditional and psychedelic therapies, with a strong emphasis on innovative formulations and advanced drug delivery systems. Leading its pipeline is SPC-15, an intranasal treatment engineered to address post-traumatic stress disorder (PTSD) and anxiety disorders stemming from stress. Another key development is SP-26, a time-release, ketamine-loaded implant designed to provide relief for fibromyalgia and chronic pain. Furthermore, Silo Pharma is advancing two preclinical programs: SPC-14, an intranasal compound targeting Alzheimer's disease, and SPU-16, a CNS-homing peptide intended for the management of multiple sclerosis (MS). The company's research and development efforts frequently involve collaborations with prominent academic institutions such as Columbia University and the University of Maryland, Baltimore. Founded in 2010, the company adopted its current name, Silo Pharma, Inc., in September 2020, having previously operated as Uppercut Brands, Inc. Silo Pharma is headquartered in Sarasota, Florida.
Business History
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -7.50
Total Equity: $6.31M
Shares: 558,818
Total Debt: $0.00
Cash: $4.75M
EBITDA: -$4.18M
Total Debt: $0.00
Cash: $4.75M
Revenue: $72,102
Shares: 558,818
Revenue: $72,102
Revenue: $72,102
Revenue: $72,102
Total Equity: $6.31M
Tax Rate: 0.0%
Equity: $6.31M
Total Debt: $0.00
Cash: $4.75M
Current Liabilities: $650,183
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $6.31M
Shares: 558,818
Shares: 558,818
CapEx: $0.00
Shares: 558,818
Stock Price: $6.05
Net Income: -$4.23M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 26, 2026 9:24am (23h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $71,264 | $72,102 | $72,102 | $72,102 | $72,102 |
| Cost of Revenue | $5,004 | $5,838 | $5,838 | $5,838 | $886,057 |
| Gross Profit | $66,260 | $66,264 | $66,264 | $66,264 | $-813,955 |
| Operating Expenses | $2.8M | $3.7M | $3.9M | $4.8M | $3.5M |
| Operating Income | -$2.7M | -$3.6M | -$3.9M | -$4.7M | -$4.3M |
| Net Income | $3.9M | -$3.9M | -$3.7M | -$4.4M | -$4.2M |
| EBITDA | $4.2M | -$3.9M | -$3.6M | -$4.4M | -$4.2M |
| EPS | $19.80 | $-25.65 | $-18.00 | $-17.85 | $-7.50 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 26, 2026 9:24am (23h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $9.8M | $11.4M | $3.5M | $3.9M | $4.7M |
| Total Current Assets | $10.4M | $11.6M | $7.7M | $7.1M | $7.4M |
| Total Assets | $10.5M | $11.6M | $7.7M | $7.4M | $7.6M |
| Current Liabilities | $490,039 | $436,318 | $775,590 | $1.7M | $650,183 |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $1.4M | $1.3M | $1.6M | $2.4M | $1.3M |
| Total Equity | $9.1M | $10.3M | $6.2M | $5.0M | $6.3M |
| Retained Earnings | -$3.3M | -$7.2M | -$10.9M | -$15.3M | -$19.5M |
Cash Flow (Annual)
Last updated: Jun 26, 2026 9:24am (23h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$2.3M | -$3.5M | -$3.2M | -$3.8M | -$4.7M |
| Capital Expenditure | $-4 | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$2.3M | -$3.5M | -$3.2M | -$3.8M | -$4.7M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $-471,121 | $-173,113 | $0 |
| Net Change in Cash | $8.7M | $1.5M | -$7.8M | $381,491 | $842,901 |
Analyst Estimates (Annual)
Last updated: Jun 26, 2026 9:09pm (11h ago)| Metric | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| Revenue |
$72,000 $72,000 – $72,000
|
$72,000 $72,000 – $72,000
|
$72,000 $72,000 – $72,000
|
$72,000 $72,000 – $72,000
|
| EBITDA |
$-43,200 $-43,200 – $-43,200
|
$-43,200 $-43,200 – $-43,200
|
$-43,200 $-43,200 – $-43,200
|
$-43,200 $-43,200 – $-43,200
|
| Net Income |
-$5.9M -$5.9M – -$5.9M
|
-$6.0M -$6.0M – -$6.0M
|
-$9.4M -$9.4M – -$9.4M
|
-$10.1M -$10.1M – -$10.1M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 26, 2026 9:24am (23h ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +1.2% | +0.0% | +0.0% | +0.0% |
| Gross Profit Growth | +0.0% | +0.0% | +0.0% | -1,328.4% |
| Operating Income Growth | -32.2% | -6.3% | -22.0% | +9.0% |
| Net Income Growth | -200.1% | +5.3% | -18.7% | +3.8% |
| EBITDA Growth | -193.3% | +7.1% | -20.8% | +4.6% |
Narrative Economics
market-narrative step).